<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Recash test site | Bisgaard Strong | Activity</title>
	<link>https://recash.wpsoul.net/members/priestshears9/activity/</link>
	<atom:link href="https://recash.wpsoul.net/members/priestshears9/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Bisgaard Strong.</description>
	<lastBuildDate>Tue, 28 Jul 2026 17:54:03 +0000</lastBuildDate>
	<generator>https://buddypress.org/?v=</generator>
	<language>en-US</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">2c9743124d78ad9c29bb28db18902fe5</guid>
				<title>Bisgaard Strong posted an update: g., by repairing SOD1 mutations or the SMN2 splicing defect [&#133;]</title>
				<link>https://recash.wpsoul.net/activity/p/137411/</link>
				<pubDate>Thu, 02 Jan 2025 12:03:31 +0000</pubDate>

									<content:encoded><![CDATA[<p>g., by repairing SOD1 mutations or the SMN2 splicing defect or deleting C9orf72 expanded repeats. These studies have shown promising results to approach therapeutic trials that should significantly lower the progression of these deadly disorders.A self-transcribing and replicating RNA (STARR)-based vaccine (LUNAR-COV19) has been developed to&hellip;<span class="activity-read-more" id="activity-read-more-137411"><a href="https://recash.wpsoul.net/activity/p/137411/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">896db0943289b8bbb1fd4da8bff9b4e4</guid>
				<title>Bisgaard Strong posted an update: Among &quot;extra-criteria&quot; antiphospholipid antibodies (aPL), [&#133;]</title>
				<link>https://recash.wpsoul.net/activity/p/122985/</link>
				<pubDate>Sat, 28 Dec 2024 13:12:38 +0000</pubDate>

									<content:encoded><![CDATA[<p>Among &#8220;extra-criteria&#8221; antiphospholipid antibodies (aPL), anti-phosphatidylserine/prothrombin (aPS/PT) antibodies, are considered a part of risk assessment strategies when investigating patients suspected of having antiphospholipid syndrome (APS). aPL detection is currently performed by solid-phase assays to identify anti-cardiolipin (aCL),&hellip;<span class="activity-read-more" id="activity-read-more-122985"><a href="https://recash.wpsoul.net/activity/p/122985/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">2dcc49c963c194b439018e86c48b2a64</guid>
				<title>Bisgaard Strong posted an update: This study aimed to explore the in vitro and in vivo roles of [&#133;]</title>
				<link>https://recash.wpsoul.net/activity/p/119408/</link>
				<pubDate>Fri, 27 Dec 2024 11:13:52 +0000</pubDate>

									<content:encoded><![CDATA[<p>This study aimed to explore the in vitro and in vivo roles of macrophages in the osteogenesis stimulated by BMP2-CPC. In vitro, the alteration of macrophage polarization and cytokine secretion induced by BMP2-CPC or CPC was investigated. The influence of conditioned medium derived from BMP2-CPC- or CPC-stimulated macrophages on the migration and&hellip;<span class="activity-read-more" id="activity-read-more-119408"><a href="https://recash.wpsoul.net/activity/p/119408/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">998e6f2c28882572467dfd82f7c8440c</guid>
				<title>Bisgaard Strong became a registered member</title>
				<link>https://recash.wpsoul.net/activity/p/95060/</link>
				<pubDate>Fri, 20 Dec 2024 17:34:02 +0000</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>